Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients

Status Withdrawn

Clinical Trial Summary

This study evaluates the efficacy of erythropoietin in refractory autoimmune encephalitis. Ten patients will receive 100 IU/kg of erythropoietin 3 times a week for 12 weeks.

Clinical Trial Description

Erythropoietin can improve the refractory autoimmune encephalitis. Erythropoietin has tissue-protective effect via activation of Janus kinase (JAK)-2, signal transducer and activator of transcription (STAT)-5 pathway and NF-kappa B pathway. The activation of JAK-2 and STAT-5 promote hemoglobin synthesis and facilitate cell cycle progression. Also, NF-kappa B pathway inhibition regulates pro-inflammatory cytokine production. We expect that erythropoietin may lead to improve the symptoms and outcome of autoimmune encephalitis. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03004209
Study type	Interventional
Source	Seoul National University Hospital
Contact
Status	Withdrawn
Phase	Phase 4
Start date	December 2016
Completion date	February 6, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04561557` - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System	Early Phase 1
Completed	`NCT05645185` - Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
Not yet recruiting	`NCT04106596` - HLA Analysis in Autoimmune Encephalitis and Related Disorders
Completed	`NCT04708626` - Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
Not yet recruiting	`NCT05711563` - Predicting and Monitoring Outcomes in Autoimmune Encephalitis
Completed	`NCT04175522` - Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:	Phase 2
Recruiting	`NCT03194815` - IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2	Phase 2
Recruiting	`NCT06079294` - Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism	N/A
Not yet recruiting	`NCT03957616` - Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
Completed	`NCT02905136` - Mechanisms of Auto-immune Encephalitis
Recruiting	`NCT05280600` - Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
Recruiting	`NCT06173076` - A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
Recruiting	`NCT03993262` - Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis	Phase 2
Recruiting	`NCT06033846` - Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis	Phase 2
Recruiting	`NCT04372615` - The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis	Phase 2
Recruiting	`NCT05177939` - Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis	Phase 3
Active, not recruiting	`NCT06432803` - Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS
Recruiting	`NCT06019975` - FDG-PET in the Diagnosis of Autoimmune Encephalitis
Completed	`NCT05783947` - Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
Not yet recruiting	`NCT06456736` - Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment